Cross-Sector entity
Alexandra Muñoz is the most frequent co-covered peer, appearing in 4 of the 4 tracked stories. The clearest coverage concentration is regulation: 3 of 4 stories, with the rest divided among 1 other category. Kelly Ryerson appears in 4 tracked Cross-Sector stories from July 12, 2026.
4 verified stories tracked
Last mentioned: Jul 12, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Alexandra Muñoz is the most frequent co-covered peer, appearing in 4 of the 4 tracked stories. The clearest coverage concentration is regulation: 3 of 4 stories, with the rest divided among 1 other category. Kelly Ryerson appears in 4 tracked Cross-Sector stories from July 12, 2026. The tracked stories average 8 original sources each.
Computed from the 4 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Kelly Ryerson. Shared-story counts are live from our verified record — not editorial picks.
The EPA's failure to deliver a promised MAHA regulatory agenda after eight months exposes the agency to accountability pressures, including potential lawsuits and legislative oversight, while raising questions about good-faith regulatory planning.
The indefinite postponement of a formal MAHA agenda means delayed federal action on pesticides and chemicals linked to America's chronic disease epidemic, frustrating health advocates and potentially costing lives.
The EPA's simultaneous retreat from a promised health agenda and aggressive environmental deregulation highlights a hollowing out of environmental governance, raising concerns about the agency's ability to address the health impacts of climate change.
The lack of a clear MAHA framework from the EPA creates uncertainty for biotech and pharma companies navigating chemical regulations, potentially affecting R&D investment, product approvals, and market positioning for bio-based alternatives.
Source: abcnews.com · durangoherald.com
